How have SNPX shares performed in 2024?

Synaptogenix's stock was trading at $6.7975 on January 1st, 2024. Since then, SNPX shares have decreased by 30.9% and is now trading at $4.70. View the best growth stocks for 2024 here .

Are investors shorting Synaptogenix?

Synaptogenix saw a decline in short interest in March. As of March 31st, there was short interest totaling 11,900 shares, a decline of 97.2% from the March 15th total of 426,600 shares. Based on an average trading volume of 40,800 shares, the short-interest ratio is presently 0.3 days. Currently, 1.1% of the shares of the stock are sold short. View Synaptogenix's Short Interest .

When is Synaptogenix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our SNPX earnings forecast .

When did Synaptogenix's stock split?

Synaptogenix's stock reverse split on Friday, April 5th 2024. The 1-25 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Synaptogenix?

Shares of SNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SNPX

Synaptogenix (SNPX) Stock Price, News & Analysis

→ I’m officially sounding the alarm. (From Altimetry) (Ad)

Free SNPX Stock Alerts

$4.70

+0.04 (+0.86%)

(As of 09:43 AM ET)

Compare

Today's Range: $4.64
▼
$4.71
50-Day Range: $3.97
▼
$6.64
52-Week Range: $3.53
▼
$47.00

Volume: 632 shs
Average Volume: 43,568 shs
Market Capitalization: $5.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Synaptogenix alerts:

Ad Altimetry

I’m officially sounding the alarm.

AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.

Just click here to watch my full uncensored interview.

About Synaptogenix Stock (NASDAQ:SNPX)

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

SNPX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SNPX Stock News Headlines

April 5, 2024 | uk.investing.com

Synaptogenix announces reverse stock split to regain Nasdaq compliance

April 4, 2024 | msn.com

What's Going On With Synaptogenix (SNPX) Stock?

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 3, 2024 | finance.yahoo.com

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

February 22, 2024 | msn.com

U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.18%

December 19, 2023 | finance.yahoo.com

Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders

December 6, 2023 | finance.yahoo.com

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

November 2, 2023 | finance.yahoo.com

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

September 26, 2023 | finance.yahoo.com

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

September 7, 2023 | finance.yahoo.com

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

July 19, 2023 | prnewswire.com

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

July 14, 2023 | benzinga.com

Short Volatility Alert: Synaptogenix Inc

July 13, 2023 | benzinga.com

Synaptogenix Shares Halted On Circuit Breaker To The Upside, Stock Now Up 59.1%

July 13, 2023 | marketwatch.com

Synaptogenix Shares Rise 48% After Alzheimer's Drug Abstract Accepted at Conference

July 13, 2023 | finance.yahoo.com

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

June 24, 2023 | finance.yahoo.com

SNPX - Synaptogenix, Inc.

March 7, 2023 | finance.yahoo.com

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

February 27, 2023 | reuters.com

SNPX.O

December 20, 2022 | msn.com

Peering Into Synaptogenix's Recent Short Interest

December 16, 2022 | seekingalpha.com

Synaptogenix crashes 69% as Phase 2 trial for Alzheimer’s candidate fails

December 16, 2022 | finance.yahoo.com

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

December 9, 2022 | seekingalpha.com

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

November 18, 2022 | seekingalpha.com

Synaptogenix announces $15M private placement with existing investors

November 18, 2022 | finance.yahoo.com

Synaptogenix Announces $15 Million Private Placement with Existing Investors

October 22, 2022 | ca.finance.yahoo.com

Companies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In Growth

October 19, 2022 | finance.yahoo.com

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

See More Headlines

Receive SNPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synaptogenix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SNPX
CUSIP: N/A
CIK: 1571934
Web: www.synaptogen.com
Phone: 973-242-0005
Fax: N/A
Employees: 5
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($26.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,040,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -22.50%
Return on Assets: -18.10%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.14
Quick Ratio: 7.14

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $25.27 per share
Price / Book: 0.18

Miscellaneous

Outstanding Shares: 1,090,000
Free Float: 1,038,000
Market Cap: $5.08 million
Optionable: Not Optionable
Beta: 1.33

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Alan J. Tuchman M.D. (Age 77)
MBA(FAAN), CEO & Director
Comp: $303.35k
Dr. Daniel L. Alkon M.D. (Age 82)
President, Chief Scientific Officer & Director
Comp: $375k
Mr. Robert Weinstein (Age 64)
CFO, Executive VP, Treasurer & Secretary
Comp: $568.92k

Key Competitors

View All Competitors

SNPX Stock Analysis - Frequently Asked Questions

How have SNPX shares performed in 2024?: Synaptogenix's stock was trading at $6.7975 on January 1st, 2024. Since then, SNPX shares have decreased by 30.9% and is now trading at $4.70.
View the best growth stocks for 2024 here.
Are investors shorting Synaptogenix?: Synaptogenix saw a decline in short interest in March. As of March 31st, there was short interest totaling 11,900 shares, a decline of 97.2% from the March 15th total of 426,600 shares. Based on an average trading volume of 40,800 shares, the short-interest ratio is presently 0.3 days. Currently, 1.1% of the shares of the stock are sold short.
View Synaptogenix's Short Interest.
When is Synaptogenix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our SNPX earnings forecast.

When did Synaptogenix's stock split?: Synaptogenix's stock reverse split on Friday, April 5th 2024. The 1-25 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
How do I buy shares of Synaptogenix?: Shares of SNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SNPX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial